RBC Capital Initiates Coverage On Neumora Therapeutics with Outperform Rating, Announces Price Target of $24
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has initiated coverage on Neumora Therapeutics (NASDAQ:NMRA) with an Outperform rating and a price target of $24.
October 10, 2023 | 9:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neumora Therapeutics has been given an Outperform rating by RBC Capital, with a price target of $24.
The Outperform rating from RBC Capital indicates that the analyst expects Neumora Therapeutics to do better than the market average. This positive outlook, coupled with a price target of $24, suggests potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100